NICE spurns Celgene's Imnovid for MM
The U.K.'s NICE issued draft guidance recommending against use of Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) in combination with dexamethasone to treat relapsed and refractory multiple myeloma (MM). The European Commission approved Imnovid last year to treat adults who have received at least two prior treatments for MM, including Celgene's Revlimid lenalidomide and Velcade bortezomib from Johnson & Johnson (NYSE:JNJ), and whose disease has progressed on the most recent therapy.
NICE said Celgene did not provide sufficient evidence showing Imnovid is more clinically effective than current therapies. NICE also said the incremental cost-effectiveness ratio (ICER) for Imnovid was more than L50,000 ($80,215) per quality-adjusted life year (QALY) gained compared with Velcade plus dexamethasone. ...